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Summary
Periodontitis is a plaque induced disease characterized
by tissue destruction. The extent of the alveolar bone
loss depends on the host response stimulated by bacte-
rial infection. Recently researchers have focused on the
role of the immune system, of RANK/RANKL/OPG path-
way and of cytokines network. Another recent field of in-
terest is osteoimmunology that try to explain the rela-
tionship between immune and bone cells in activating
bone resorption. Advances in the understanding of the
pathogenic mechanisms allowed a better understanding
of the relationship with other diseases like osteoporosis
and also to hypothesize new therapies based on modula-
tion of host response (host modulatory therapy - HMT).
The purpose of this mini-review is to briefly discuss
these topics.
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Background
Periodontitis is defined by the American Academy of Peri-
odontology (AAP) as “Inflammation of the supporting tissues
of the teeth. Usually a progressively destructive change
leading to loss of bone and periodontal ligament. An exten-
sion of inflammation from gingiva into the adjacent bone and
ligament” (1). The disease is an opportunistic infection asso-
ciated to plaque on soft (gingiva) and hard (tooth) tissue (2-
4). Plaque is an organized mass, consisting mainly of mi-
croorganisms that adheres to teeth, prostheses and oral sur-
faces (1). The subgingival bacterial plaque is necessary, but
not sufficient to develop the disease. In fact, if on the one
hand we find the infection determined by the plaque on the
other we find the host defense. The latter will be determined
by modifiable or not-modifiable (genetic) risk factors (5-10).
The role of the immune system: T cells
In the past, for many years, Authors analyzed the role of
bacterial plaque. Today, since it was introduced the concept
of “Osteoimmunology”, the Authors have focused on the sig-
naling between cells of the immune system and cells of the
bone (11, 12).
The early stages of infection activate the non-specific im-
mune defenses. These include mechanical barriers and ini-
tial inflammatory response. Later, lymphocytes T and lym-
phocytes B are activated when bacteria invade the tissues or
when macrophages and other cells (APCs) present the anti-
gen. Recently, researchers are considering T cells as regula-
tors of bone turnover, not only in the case of periodontal dis-
ease but also in other diseases (13). In fact T cells activates
the macrophages, can activate indirectly the osteoclasts and
their precursors and also directly expressing RANKL (14).
Brunetti et al. demonstrate that the samples of lymphocytes
T from patients affected by periodontitis show over-expres-
sion of RANKL and TNF-alfa compared to healthy controls
(13). The role of RANKL and TNF-alfa in activating osteo-
clasts is demonstrated also for other diseases like osteo-
porosis and rheumatoid arthritis (15).
The T cells can be activated also by the toll like receptors
(TLRs), which bind bacterial structures. The heterodimers
TLR2/TLR6 and TLR2/TLR1 determine mandibular bone re-
sorption mediated by PGE2 in periodontal disease (16, 17).
Moreover activated TLRs start an intracellular cascade that
leads to the production of cytokines involved directly or indi-
rectly in osteoclasts activation (18).
It is know that T cells produce “pro-resorptive” cytokines (IL-
1, IL-6, IL-11) when properly stimulated. Cytokines act in a
network with the cells, however the relationship with clinical
manifestations of periodontal diseases is not clear (19, 20).
During the last years researchers have focused on Th-17, a
subpopulation of lymphocytes T characterized by the produc-
tion of IL-17. This cytokine seems to be strongly correlated
to tissue destruction (21).
These recent findings suggest a primary role of the immune
system in alveolar bone resorption due to periodontal dis-
ease.
RANK/RANKL/OPG pathway in periodontal disease
The current knowledge suggest that RANK/RANKL/OPG
pathway seems to be the bottle-knee, of metabolic ways of
inflammation, to activate bone resorption in patients affected
by periodontal disease (22, 23); RANKL activates bone re-
sorption, while OPG has inhibition functions. Different Au-
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thors have investigated RANKL/OPG ratio in periodontitis.
Some studies have demonstrated a RANKL/OPG ratio aug-
mented in serum/plasma of patients affected by periodontitis
reporting low level of OPG (24-26). Cochran in a review of
literature has found that RANKL/OPG ratio is augmented in
saliva and gingival crevicular fluid (GCF) of patients affected
by periodontitis compared with healthy controls, however
there is heterogeneity between selected studies (20). In an-
other review Belibasakis and Bostanci have reported in-
creased RANKL/OPG ratio underlining that RANKL is up-
regulated, whereas OPG is down-regulated in periodontitis
compared to healthy control, that the ratio is further up-regu-
lated in smokers and diabetics, and that is not affected by
conventional periodontal treatment (27). Nowadays there are
not sufficient data to correlate RANKL/OPG ratio in biofluids
(saliva, GCF, serum/plasma) to clinical expression of peri-
odontitis, so the RANKL/OPG ratio cannot be considered a
valid marker of pathology. 
Periodontitis and osteoporosis
For patients suffering form of aggressive periodontitis or for
patients not responding to classical therapy is recommended
a deep clinical investigation. Considering the age of the pa-
tients, we search for other diseases that can be linked to pe-
riodontitis; one of these diseases is the osteoporosis (Figure
1). In literature we can find numerous studies and also some
systematic reviews which analyze the relationship between
osteoporosis and periodontitis. Groen in the late ’60 was the
first Author to propose the association (28).
Considering the common risk factors like age, genetics,
smoke, alcohol, diabetes, and that, despite different etiology,
the diseases have a common final step which is bone re-
sorption, researchers developed two hypothesis. An hypoth-
esis suggests that osteoporosis can accelerate alveolar bone
resorption in case of periodontitis. Vice versa the other hy-
pothesis suggests that infections by parodontopathogens
can promote directly and indirectly an inflammatory systemic
status, which activates the osteoclast cells (29-31).
Data retrieved from literature are about three areas of inter-
ests:
- clinical parameters of periodontitis (PD, CAL) and diag-
nosis of osteoporosis; 
- systemic and alveolar bone mineral density;
- effects of the osteoporosis medications on periodontitis
and vice versa. 
In a recent review Guglia et al. (32) searched for studies re-
lating systemic BMD to clinical parameters of periodontitis
(pocket depth, clinical attachment level, alveolar bone height
and teeth loss). The included studies report conflicting re-
sults, however different Authors suggest a positive relation-
ship between the diseases. The results of this review are dif-
ficult to analyze because of methodological variability, small
samples and different parameters of diagnosis for periodonti-
tis. Considering different parameters of diagnosis, Passos et
al. (33) showed that in the same group of patients the preva-
lence of periodontitis ranged from 24 to 98,6%. 
In literature there are different index of bone mandibular den-
sity measured on routine dental radiography proposed by re-
searchers. Independently by the method used almost all
studies found an association between mandibular bone den-
sity and systemic bone density measured at spine or femur
(32, 34). Therefore it is possible for dentists to do screening
of osteoporosis on the basis of routine dental radiography. 
Although there are many drugs to treat osteoporosis, the ef-
fects of osteoporosis medications on periodontal disease are
the least investigate. The hormone replacement therapy
(HRT) seems to reduce the number of teeth lost due to peri-
odontitis, to improve mandibular bone density and reduce
gingival bleeding (35, 36). The administration of teriparatide
in an animal model of periodontitis reduces the alveolar bone
resorption, however augments the prevalence of osteosarco-
ma (37-39). Two RCTs on human demonstrate that patient
affected by periodontitis and treated with periodontal therapy
and administration of alendronate (10mg/die for 6 months)
Figure 1 - Diseases that can promote periodontitis.
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suffer less alveolar bone resorption compared to patients
treated with only periodontal therapy (34, 39). These data
are few to draw any conclusions.
Future treatments
The treatment of periodontitis widely accepted is based on: 
- infection control obtained removing supragingival and
subgingival plaque (scaling, root planing or debride-
ment);
- instructions for oral hygiene at home;
- interventions on modifiable risk factors.
Recently, considering the better understanding of the role of
immune system and of the RANK/RANKL/OPG pathway, is
emerged the modern concept of Host modulatory therapy
(HMT). The HMTs aims to reduce the tissue destruction and
to inhibit over-expression of inflammatory response (40, 41).
The HMT offers local or systemic possibilities (42):
• Systemic administered: 
- agents acting against MMPs (sub-antimicrobical ad-
ministration of doxicicline, 20mg/die for 180 days as
approved by FDA);
- tetracycline analogues; 
- agents acting against arachidonic acid metabolites
(NSAIDs); 
- lipid inflammatory mediators as target for HMT (re-
solvine, protectine, maresine); 
- agents acting on cytokines; 
- agents acting against bone resorption (bisphospho-
nate, OPG); 
- modulation of nitric oxide synthase (resveratrol); 
- probiotics, periodontal vaccines, nutrients.
• Local administered: enamel matrix proteins; PDGF; local
bisphosphonate; local NSAIDs; hypochlorous acid and
taurine-N-Monochloramine; Cimetidine.
Different Authors reported that the administration of OPG in
an animal model of periodontitis is protective for alveolar
bone resorption (43, 44). HMTs seem to offer the potential to
move periodontal treatment to a higher level, however data
are few and inconsistent.
Conclusion
Periodontal disease is characterized by the destruction of
the supporting tissues of the tooth. The mechanisms that
lead to bone resorption are similar to those of other diseases
such as osteoporosis. Despite recent acquisitions regarding
the role of the immune system, the cytokine network and
RANK/RANKL/OPG pathway, we need further studies to bet-
ter explain bone resorption mechanisms.
Most of the Authors suggest a correlation between osteo-
porosis and periodontal disease but the clinical relationship
still has not been well demonstrated, however dentist can
screen the osteoporosis on routine dental radiography.
The HMTs seem to be promising to stabilize and improve the
results of classical periodontal therapy.
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